A Retrospective Study Of Oxaliplatin Combined With S-1(SOX) As First-line Treatment In70Cases With Advanced Gastric Cancer

Purpose:To evaluate the clinical efficiency and safety of Oxaliplatin combined with S-1(SOX) as first-line treatment in advanced gastric cancer, as well as analysis the prognostic factor in patients with gastric cancer.Methods:Retrospectively reviewed patients with advanced gastric cancer who were treated with SOX as first-line treatment between October,2010and October,2014in Sir Run Run Shaw Hospital. Treatment efficiency and side effects among patients were regularly evaluated. The primary endpoint were median progression-free survival (mPFS) and median overall survival time (mOS), the secondary endpoints were response rate (RR) and disease control rate(DCR). The survival curves were depicted by Kaplan-Meier method. Using the Cox proportional hazard model to evaluate the prognostic factors and prognostic indices for overall survival.Results:70patients in stage IV at baseline evaluation were enrolled in this study. The ratio of males to females was40to30. The mean patient age was57.16±11.50years (29-77 years). The mean number of chemotherapy cycle was5.07±1.83(2-8). Of the70patients,3patients (4.3%) achieved a complete response after treatment, and19patients (27.1%) achieved partial response.29patients (41.5%) evidenced a stable disease, and19patients (27.1%) progressed during the course of the treatment. The response rate was31.4%, and disease control rate was76%. The mPFS was7.7months (95%CI5.1-10.3months), the mOS was12.1months (95%CI9.3-14.9months). The main adverse events included myelosuppression, gastrointestinal reactions and peripheral nerve toxicity, mainly in grade1-2. No case of treatment-related death was observed. The ECOG score, number of chemotherapy cycle and level of serum CEA were found to be significant predictors of OS by Cox proportional hazards model.Conclusion:While Oxaliplatin and S-1are used together to treat advanced gastric cancer, the approach can slow down the advancement of the disease, achieve high clinical benefits, slight side effects was well tolerance among patients, it has a bright prospect for application. Patients with better performance status, low level of CEA might have more pronounced survival benefit.